-
Bafna S, Singh A P, Moniaux N. MUC4, a multifunctional transmembrane glycoprotein, induces oncogenic transformation of NIH3T3 mouse fibroblast cells[J]. Cancer Res, 2008, 68(22): 9231-9238. doi: 10.1158/0008-5472.CAN-08-3135
-
Bequet-Romero M, Lopez-Ocejo O. Angio-genesis modulators expression in culture cell lines positives for HPV-16 oncoproteins[J]. Biochem Biophys Res Commun, 2000, 277(1): 55-61. doi: 10.1006/bbrc.2000.3628
-
Edmonds C, Vousden K H. A point mutational analysis of human papillomavirus type 16 E7 protein[J]. J Virol, 1989, 63(6): 2650-2656.
-
Hung C F, Monie A, Weng W H. DNA vaccines for cervical cancer[J]. Am J Transl Res, 2010, 2(1): 75-87.
-
Lopez-Ocejo O, Viloria-Petit A, Bequet-Romero M. Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner[J]. Oncogene, 2000, 19(): 4611-4620. doi: 10.1038/sj.onc.1203817
-
Nadagawa S, Watanabe S, Yoshikawa H. Mutational Analysis of Human Papillomavirus Type 16 E6 Protein: Transforming Function for Human Cells and Degradation of p53 in vitro[J]. Virology, 1995, 212(2): 535-542. doi: 10.1006/viro.1995.1511
-
Ohlschläger P, Quetting M, Alvarez G. Enhancement of immunogenicity of a therapeutic cervical cancer DNA-based vaccine by co-application of sequenceoptimized genetic adjuvants[J]. Int J Cancer, 2009, 125(1): 189-198. doi: 10.1002/ijc.v125:1
-
Toussaint-Smith E, Donner D B, Roman A. Expression of human papillomavirus type 16 E6 and E7 oncoproteins in primary foreskin keratinocytes is sufficient to alter the expression of angiogenic factors[J]. Oncogene, 2004, 23(): 2988-2995. doi: 10.1038/sj.onc.1207442
-
Walboomers J M, Jacobs M V, Manos M M. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide[J]. J Pathol, 1999, 189(): 12-19. doi: 10.1002/(ISSN)1096-9896
-
Watanabe S, Kanda T, Sato H. Mutational analysis of human papillomavirus type 16 E7 functions[J]. J Virol, 1990, 64(1): 207-214.
-
Yan J, Reichenbach D K, Corbitt N. Induction of antitumor immunity in vivo following delivery of a novel HPV-16 DNA vaccine encoding an E6/E7 fusion antigen[J]. Vaccine, 2009, 27(3): 431-440. doi: 10.1016/j.vaccine.2008.10.078
-
Zhou X S, Qian X L, Zhao Q Z. Efficient expression of modified human papillomavirus 16 E6/E7 fusion protein and the antitumor efficacy in a mouse model[J]. Biol Pharm Bull, 2004, 27(3): 303-307. doi: 10.1248/bpb.27.303